V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330009334 | 330006137 | 1.76 | 8.5 | Curative (C) | 2017-12-16 | 2017-12-22 | Mitotane 5.5 - 10g | N | N | 330021961 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 330009335 | 330009346 | null | 64.5 | Curative (C) | 2017-11-03 | 2017-11-04 | Doxorubicin + Gemcitabine | N | null | 330022129 | AML17 TRIAL |
| 330009336 | 330009346 | 1.91 | null | Palliative (P) | 2014-01-05 | 2014-01-05 | DHAP | 2 | N | 330022129 | UKALL2014 |
| 330009337 | 330006139 | 1.8 | 83 | Palliative (P) | 2016-12-25 | 2017-02-22 | VINCRISTINE | N | N | 330022918 | TOPOTECAN |
| 330009338 | 330006141 | 1.69 | 80.5 | Curative (C) | null | 2016-12-10 | CVP R | null | null | 330022920 | CARBOPLATIN + CETUXIMAB + FU |
| 330009339 | 330006142 | null | null | Curative (C) | 2016-06-16 | 2016-06-20 | Cyclophosphamide High Dose | N | null | 330023337 | IVA |
| 330009340 | 330006142 | null | null | Curative (C) | 2016-12-27 | 2017-01-23 | ALL UKALL2011 Ind A Sht Dex (PAsp) | N | N | 330023337 | TOPOTECAN |
| 330009341 | 330012899 | 1.68 | 64.8 | Palliative (P) | 2017-03-16 | 2017-03-19 | DACTINOMYCIN + CYCLO + VINCRISTINE | 2 | N | 330023936 | BEP |
| 330009342 | 330013268 | null | 70 | c | 2015-10-29 | 2015-12-02 | Dox + HD Mtx (post PAM) | N | N | 330024602 | IFOSFAMIDE |
| 330009343 | 330006143 | 1.77 | null | Disease modification (D) | 2016-01-09 | 2016-01-13 | ALL UKALL2011 Consolidation A | N | N | 330024623 | BEVACIZUMAB + IRINOTECAN |
| 330009344 | 330006145 | 1.69 | null | Adjuvant (A) | 2018-11-27 | 2018-11-27 | RUXOLITINIB | 02 | N | 330024781 | CARBOPLATIN + PEMETREXED |
| 330009345 | 330006146 | 1.77 | null | null | 2016-12-07 | 2016-12-14 | STS Rhabdomyosarcoma RMS 2005 IVA | N | null | 330025015 | RMS 2005 TRIAL |
| 330009346 | 330006149 | null | 71.6 | Curative (C) | null | 2017-08-06 | DACTINOMYCIN + CYCLO + VINCRISTINE | null | null | 330003175 | CVP R |
| 330009347 | 330006151 | 0 | null | Palliative (P) | 2017-02-03 | 2017-04-28 | DACTINOMYCIN + CYCLO + VINCRISTINE | 01 | N | 330007206 | IBRUTINIB |
| 330009348 | 330011098 | 0 | 57 | Palliative (P) | 2018-11-08 | 2018-11-11 | CISPLATIN + DOXORUBICIN + ETOPOSIDE | 02 | null | 330007206 | CVP R |
| 330009349 | 330006160 | 1.79 | 72.3 | Palliative (P) | 2014-12-09 | 2014-12-15 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | N | 330015629 | CHLORAMBUCIL + RITUXIMAB |
| 330009350 | 330009354 | 1.61 | 94.4 | Palliative (P) | 2017-01-23 | 2017-02-13 | TRASTUZUMAB | N | N | 330016446 | MITOTANE |
| 330009351 | 330009354 | 1.79 | 70 | Disease modification (D) | 2017-04-30 | 2017-05-05 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 330016446 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330009352 | 330006161 | 1.74 | 69.6 | Palliative (P) | 2018-05-24 | 2018-07-08 | CAP | N | N | 330020726 | IMATINIB |
| 330009353 | 330009355 | 1.54 | 40 | Palliative (P) | 2019-04-30 | 2019-04-30 | Ipilimumab | N | N | 330020928 | UKALL2014 |
| 330009354 | 330009355 | null | 29.1 | Palliative (P) | 2017-04-02 | 2017-06-21 | Carboplatin + Doxorubicin | 02 | N | 330020928 | BEP |
| 330009355 | 330006165 | 0 | null | Curative (C) | 2017-04-15 | 2017-04-25 | Cytarabine Low Dose | N | null | 330000232 | LENALIDOMIDE |
| 330009356 | 330009356 | null | 15.3 | Palliative (P) | null | 2019-05-13 | CARBOPLATIN + CYCLOPHOSPHAMIDE + ETOPOSIDE | null | null | 330020943 | CLOFARABINE + CYTARABINE |
| 330009357 | 330002930 | null | 42.1 | Palliative (P) | 2014-12-23 | 2016-06-07 | EW Rel rEECur Gemcitabine/Docetaxel | N | Y | 330000004 | NOT MATCHED |
| 330009358 | 330002935 | null | 92.7 | Curative (C) | 2015-01-12 | 2015-01-14 | CNS LGG2004 03 vinc + carbo | 2 | null | 330000049 | NOT MATCHED |
| 330009359 | 330002936 | null | null | Curative (C) | 2013-10-04 | 2013-10-04 | NB HRNBL-1 ch14.18/CHO(trial) +IL-2 | null | Y | 330000050 | NOT MATCHED |
| 330009360 | 330007579 | 1.81 | 70.6 | Adjuvant (A) | 2015-02-14 | 2015-02-14 | NB HRNBL-1 COJEC Ind COURSE B | 02 | null | 330000059 | NOT MATCHED |
| 330009361 | 330002942 | 1.6 | 14.8 | Palliative (P) | 2015-12-16 | 2015-12-17 | CNS GCT II Germinoma - Ifos Etop | N | N | 330000065 | NOT MATCHED |
| 330009363 | 330002947 | null | 73.2 | null | 2015-12-29 | 2016-02-01 | Cisplatin + Radiotherapy | 02 | Y | 330000076 | CISPLATIN + RT |
| 330009366 | 330002953 | 1.57 | 9.7 | Curative (C) | 2017-12-25 | 2017-12-25 | EW EuroEwing 2012 Arm B VC | Y | Y | 330000102 | NOT MATCHED |
| 330009367 | 330002957 | null | 14.1 | Curative (C) | 2014-01-09 | 2014-04-06 | NB HRNBL-1 BUMEL MAT | N | null | 330000122 | NOT MATCHED |
| 330009368 | 330002959 | 1.69 | 64.8 | Curative (C) | 2013-08-31 | 2014-04-20 | Cisplatin 100 + RT(H&N) 1 day | N | Y | 330000128 | CISPLATIN + RT |
| 330009369 | 330002960 | 0 | null | Neo-adjuvant (N) | 2017-11-14 | 2017-11-22 | NB HRNBL-1 COJEC Ind COURSE C | 2 | N | 330000144 | NOT MATCHED |
| 330009370 | 330002964 | 0.96 | null | Palliative (P) | 2014-11-25 | 2015-02-23 | CISPLATIN + DACTINOMYCIN + ETOPOSIDE + FILGRASTIM + METHOTREXATE | null | N | 330000146 | NOT MATCHED |
| 330009371 | 330002965 | null | 13.3 | Curative (C) | 2015-10-03 | 2015-10-06 | NB HRNBL-1 ch14.18/CHO only (trial) | null | null | 330000160 | NOT MATCHED |
| 330009372 | 330002966 | null | 22 | Adjuvant (A) | 2017-07-16 | 2018-03-11 | NB HRNBL-1 COJEC Ind COURSE B | 02 | N | 330000163 | NOT MATCHED |
| 330009373 | 330002970 | null | 22.5 | Curative (C) | 2016-06-14 | 2017-01-31 | NB HRNBL-1 COJEC Ind COURSE C | 02 | N | 330000172 | NOT MATCHED |
| 330009374 | 330007592 | 1.71 | 52.2 | Adjuvant (A) | 2017-11-09 | 2017-11-29 | Cisplatin + Radiotherapy | N | N | 330000180 | CISPLATIN + RT |
| 330009375 | 330002977 | 1.73 | 12.1 | Curative (C) | 2014-01-27 | 2014-01-27 | NB 13 cis-RA (Isotretinoin) | 02 | N | 330000182 | NOT MATCHED |
| 330009376 | 330002979 | 1.6 | null | Curative (C) | 2014-03-26 | 2014-03-30 | Cisplatin 100 + RT(H&N) 1 day | N | Y | 330000234 | CISPLATIN + RT |
| 330009377 | 330002980 | 1.76 | 53.1 | Adjuvant (A) | 2014-08-08 | 2014-09-11 | Cisplatin 100 + RT(H&N) 1 day | 02 | null | 330000236 | CISPLATIN + RT |
| 330009378 | 330002982 | null | 15.2 | Curative (C) | 2014-03-05 | 2014-06-08 | Amsacrine + ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT) + BUSULFAN + CYTARABINE + FLUDARABINE | 01 | N | 330000242 | NOT MATCHED |
| 330009379 | 330002987 | 0 | 24.7 | Curative (C) | 2016-10-14 | 2016-11-04 | EW EuroEwing 2012 Arm B VC | N | N | 330000247 | NOT MATCHED |
| 330009380 | 330002990 | 0 | 46.4 | Curative (C) | 2013-07-01 | 2013-10-05 | NB HRNBL-1 COJEC Ind COURSE B | 02 | N | 330000262 | NOT MATCHED |
| 330009381 | 330007599 | 0 | 13 | Neo-adjuvant (N) | 2016-11-13 | 2016-11-13 | CNS PNET III Vinc, Cyclo, Etoposide | N | N | 330000263 | NOT MATCHED |
| 330009382 | 330010140 | 0.78 | 29.3 | Curative (C) | 2015-11-12 | 2016-03-15 | NB HRNBL-1 COJEC Ind COURSE B | 02 | Y | 330000276 | NOT MATCHED |
| 330009383 | 330002996 | 0 | 52.2 | Neo-adjuvant (N) | 2015-05-22 | 2015-05-29 | NB HRNBL-1 COJEC Ind COURSE B | N | N | 330000277 | NOT MATCHED |
| 330009384 | 330002998 | null | 14.3 | Neo-adjuvant (N) | 2016-07-11 | 2016-07-11 | CNS LGG Temozolomide | 1 | null | 330000287 | NOT MATCHED |
| 330009385 | 330002999 | null | 16.4 | Curative (C) | 2017-08-12 | 2017-08-31 | NB HRNBL-1 COJEC Ind COURSE B | N | N | 330000299 | NOT MATCHED |
| 330009386 | 330003003 | 0 | 47.5 | Curative (C) | null | 2014-09-21 | NB HRNBL-1 BUMEL MAT | 01 | N | 330000305 | NOT MATCHED |